Also, HER2 can be clinically correlated with stem/progenitor cell populations in that patients with HER2+ breast cancers treated with the HER2 inhibitor lapatinib show a significant reduction in the number of CD44+/CD24–/low cells and a decreased tumorsphere-forming efficiency [12,75,76]. This evidence concerns the gene CD44 and breast carcinoma.